Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy.
By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes.
Translational Breast Cancer Genomics Lab; Cancer Therapeutics Program; Peter MacCallum Cancer Centre; St. Andrews Place; East Melbourne, VIC Australia ; Sir Peter MacCallum Department of Oncology; University of Melbourne; Parkville, VIC Australia.
Sherene
S
Loi
biomarkers; breast cancer; immunotherapies; prognosis; trastuzumab efficacy; tumor infiltrating lymphocytes